Skip to main content

Retraction Note to: LATS2 overexpression attenuates the therapeutic resistance of liver cancer HepG2 cells to sorafenib‑mediated death via inhibiting the AMPK–Mfn2 signaling pathway

Retraction to: Cancer Cell Int (2019) 19:60 https://doi.org/10.1186/s12935-019-0778-1

The editor has retracted this article [1] because Fig. 2f has been duplicated from Fig. 6j in a previously published article [2]. In addition, the article contains sections that substantially overlap with a previously published article [3]. The data reported in this article are therefore unreliable.

Xue Shao agrees to this retraction. Jie Song, Wei Zhao, and Chang Lu have not responded to any correspondence from the editor/publisher about this retraction.

References

  1. 1.

    Song J, Zhao W, Lu C, Shao X. LATS2 overexpression attenuates the therapeutic resistance of liver cancer HepG2 cells to sorafenib-mediated death via inhibiting the AMPK–Mfn2 signaling pathway. Cancer Cell Int. 2019;19:60. https://doi.org/10.1186/s12935-019-0778-1.

    Article  PubMed  PubMed Central  Google Scholar 

  2. 2.

    Jieensinue S, Zhu H, Li G, Dong K, Liang M, Li Y. Tanshinone IIA reduces SW837 colorectal cancer cell viability via the promotion of mitochondrial fission by activating JNK-Mff signaling pathways. BMC Cell Biol. 2018;19:21. https://doi.org/10.1186/s12860-018-0174-z.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  3. 3.

    Hou Y, Lan C, Kong Y, Zhu C, Peng W, Huang Z, Zhang C. Genetic ablation of TAZ induces HepG2 liver cancer cell apoptosis through activating the CaMKII/MIEF1 signaling pathway. OncoTargets Ther. 2019;12:1765–79. https://doi.org/10.2147/OTT.S196142.

    CAS  Article  Google Scholar 

Download references

Author information

Affiliations

Authors

Corresponding author

Correspondence to Xue Shao.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Song, J., Zhao, W., Lu, C. et al. Retraction Note to: LATS2 overexpression attenuates the therapeutic resistance of liver cancer HepG2 cells to sorafenib‑mediated death via inhibiting the AMPK–Mfn2 signaling pathway. Cancer Cell Int 19, 359 (2019). https://doi.org/10.1186/s12935-019-1084-7

Download citation